Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Vera Therapeutics (NASDAQ:VERA) announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026 at 2:15 PM PST.

The team will participate in one-on-one investor meetings and provide a live webcast at the conference link. A replay will be available for 90 days via the company's Investor Calendar.

Key Figures

Conference dates January 12–15, 2026 44th Annual J.P. Morgan Healthcare Conference

Presentation date January 13, 2026 Company presentation at J.P. Morgan conference

Presentation time 2:15 PM PST Scheduled conference presentation slot

Webcast replay period 90 days Duration replay available on Investor Calendar

Share price $48.68 Price before conference participation news

1-day change 4.64% Move over prior 24 hours

52-week high $56.05 Upper end of 52-week trading range

52-week low $18.53 Lower end of 52-week trading range

Market Reality Check

$48.71 Last Close

Volume Volume 1,124,634 vs 20-day average 1,399,809 (relative volume 0.8). normal

Technical Price 48.68 is trading above 200-day MA at 27.48.

Peers on Argus

Peers showed mixed moves: AUPH +2.1%, ARDX +3.92%, EWTX +5.93%, VRDN -2.86%, CDTX roughly flat (+0.03%), suggesting stock-specific factors rather than a uniform sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 09	Equity offering priced	Negative	-0.8%	Underwritten offering of 6.14M shares at $42.50 for ~$261M proceeds.
Dec 08	Equity offering proposed	Negative	+0.3%	Plan to sell $200M of Class A stock from existing shelf registration.
Dec 05	Inducement grants	Neutral	+0.3%	Stock options and RSUs granted to seven new employees under inducement plan.
Nov 26	Board appointment	Positive	+13.3%	Veteran executive James R. Meyers joins board as company readies atacicept launch.
Nov 24	Investor conferences	Neutral	+2.7%	Management presentations and 1x1s at Evercore and Citi healthcare conferences.

Pattern Detected

Recent news reactions mostly aligned with the qualitative tone: positive clinical and management updates saw gains, while financing and routine items produced modest or muted moves.

Recent Company History

Over the last few months, Vera reported several notable events. A late November 2025 board appointment tied to preparations for an atacicept launch coincided with a 13.25% gain, and investor conference participation on Nov 24, 2025 also saw a positive reaction. In early December, inducement equity grants produced a small uptick, while a proposed and then priced equity offering in mid-December led to only modest share moves. Against this backdrop, the new J.P. Morgan Healthcare Conference participation fits a pattern of frequent investor outreach and corporate visibility updates.

Market Pulse Summary

This announcement highlights Vera’s participation in a high-profile healthcare conference, with a scheduled presentation on January 13, 2026 and a webcast replay available for 90 days. It continues a pattern of active investor engagement following prior conference appearances and corporate updates. In assessing this news, investors may monitor how management’s messaging evolves relative to recent regulatory filings, leadership changes, and the company’s broader late-stage clinical and commercial objectives.

Key Terms

biotechnology medical

"a late clinical-stage biotechnology company focused on developing and"

Biotechnology is the use of living cells, molecules, or biological processes as tools to create products, treatments, or industrial processes—think of it as using nature’s toolbox to solve problems like disease, food production, or pollution. For investors it matters because biotech ventures can deliver big breakthroughs and rapid growth but also face long development timelines, strict regulatory checks, and binary outcomes (success or failure), so potential reward comes with significant risk and uncertainty.

immunologic diseases medical

"treatments for patients with serious immunologic diseases, today announced"

Immunologic diseases are conditions where the body’s immune system either attacks its own tissues or reacts improperly to harmless substances, like a home security system that mistakes family members for intruders or overreacts to dust. They matter to investors because they drive demand for long-term treatments, influence clinical trial risks and regulatory reviews, and create sizable markets for drugs, diagnostics and medical devices, affecting company revenues and valuation.

webcast technical

"Time: 2:15 PM PSTWebcast: https://jpmorgan.metameetings.net/events/"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will present at the 44^th Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12-15, 2026. The management team will also participate in one-on-one investor meetings.

Presentation Details:
Date: Tuesday, January 13, 2026
Time: 2:15 PM PST
Webcast: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317196-vera-therapeutics-inc/webcast?gpu_only=true&kiosk=true

A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.

About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868.

Forward-Looking Statements
Statements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the plans, commitments, aspirations and goals under the caption “About Vera Therapeutics”. These forward-looking statements are based upon Vera Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, risks and uncertainties associated with Vera Therapeutics’ business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics' filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jalllaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

FAQ

When will Vera Therapeutics (VERA) present at the J.P. Morgan Healthcare Conference?

Vera Therapeutics will present on January 13, 2026 at 2:15 PM PST.

How can I watch the Vera Therapeutics (VERA) webcast from the January 13, 2026 presentation?

Watch live via the provided conference webcast link; a replay is available for 90 days on the company's Investor Calendar.

Will Vera Therapeutics management hold investor meetings at J.P. Morgan Healthcare Conference 2026?

Yes, the management team will participate in one-on-one investor meetings during the conference (Jan 12-15, 2026).

Where can investors find the replay of Vera Therapeutics (VERA) presentation after January 13, 2026?

The replay can be accessed for 90 days via the Vera Therapeutics Investor Calendar on the company's website.

What topics will Vera Therapeutics (VERA) cover at the January 13, 2026 presentation?

The company said management will present on recent developments and the company outlook; specific slide topics will be shared during the presentation.

Is the Vera Therapeutics (VERA) presentation at J.P. Morgan open to the public?

The live webcast is publicly available via the conference link; one-on-one investor meetings are by appointment.